A carregar...
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer
Strategies for successful primary treatment of HER2-positive breast cancer include use of the HER2 inhibitors trastuzumab or lapatinib in combination with standard chemotherapy. While successful, many patients develop resistance to these HER2 inhibitors indicating an unmet need. Consequently, curren...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4821489/ https://ncbi.nlm.nih.gov/pubmed/27045589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0153025 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|